Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 34Recurrence 4Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Plasmacytoma 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Dexamethasone 2Calcium Dobesilate 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2venetoclax 1ixazomib 1daratumumab 1belantamab mafodotin 1X-Rays 1Stem Cell Transplantation 1Phantoms, Imaging 1Melphalan 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × daratumumab × 30 days × Clear all
NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡